Tradestie Institutional Equity Comparison Engine

SVRA vs BCAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SVRA Overall Edge

SVRA Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Savara Inc. (SVRA) driven by superior Valuation, Momentum & Technical, Options & Structure while BCAX counters with relative strength in Growth & Margin. Fundamentally, SVRA trades at 0.4x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BCAX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SVRA sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SVRA
SVRA 0.4x vs BCAX N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner SVRA
1Y +4.8% vs -31.6% ยท 52W Pos 15% vs 8%
Options & Structure Winner SVRA
BREAKDOWN (17th %ile IV) vs BREAKDOWN (23rd %ile IV)
SVRA NASDAQ
Savara Inc.
Pharmaceutical Preparations
$4.46
-3.77% 1D
Market Cap $1.0B
1M Return +0.34%
1Y Return +4.81%
Forward P/E 0.4x
Unified AI Score
55.6 / 100 HOLD
Tech 30.0 Fund 54.0 Flow 70.0 Mom 54.0
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SVRA +4.81% BCAX -31.63% Spread: +36.44 pp (SVRA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SVRA TTM Op. Margin: 0.0% BCAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRA vs BCAX. Trailing 12-month operating profitability (SVRA 0.0% vs BCAX 0.0%) and valuation multiples (SVRA 0.4x vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SVRA (6) vs BCAX (1)
Institutional Metric SVRA BCAX Criterion Row Winner
Market Capitalization Scale $1.0B $665.2M Larger Scale SVRA
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SVRA
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SVRA
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -151.0% -54.2% Higher ROE BCAX
52-Week Range Position Momentum 15% ($4โ€“$7) 8% ($8โ€“$31) Stronger Trend SVRA
Beta / 30D Volatility Risk Regime 1.47ฮฒ ยท 73% Vol 1.42ฮฒ ยท 184% Vol Lower Realized Risk SVRA
Unified Institutional Score Composite Signal 55.6 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite SVRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SVRA vs BCAX Buy Guide
SVRA BREAKDOWN
92d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live SVRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SVRA nor BCAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.